Cabaletta Bio (NASDAQ:CABA) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Posted by Brenda Bartman on Aug 13th, 2026

Cabaletta Bio (NASDAQ:CABA – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03, FiscalAI reports.

Cabaletta Bio Price Performance

CABA stock traded down $0.12 during midday trading on Thursday, reaching $2.73. 1,869,582 shares of the company were exchanged, compared to its average volume of 3,707,494. Cabaletta Bio has a one year low of $1.40 and a one year high of $4.23. The firm has a market capitalization of $444.31 million, a price-to-earnings ratio of -1.39 and a beta of 3.30. The business has a 50-day moving average price of $2.91 and a two-hundred day moving average price of $3.07.

Institutional Investors Weigh In On Cabaletta Bio

Several hedge funds have recently bought and sold shares of the stock. Comerica Bank lifted its holdings in Cabaletta Bio by 2,292.1% during the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock worth $58,000 after purchasing an additional 39,860 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Cabaletta Bio during the fourth quarter worth $58,000. Tower Research Capital LLC TRC boosted its position in shares of Cabaletta Bio by 695.6% in the second quarter. Tower Research Capital LLC TRC now owns 51,036 shares of the company’s stock valued at $78,000 after acquiring an additional 44,621 shares during the period. Invesco Ltd. grew its stake in shares of Cabaletta Bio by 357.1% in the first quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock valued at $85,000 after acquiring an additional 48,181 shares in the last quarter. Finally, LPL Financial LLC bought a new position in Cabaletta Bio during the fourth quarter worth about $93,000.

Analyst Ratings Changes

CABA has been the subject of several research analyst reports. Wall Street Zen lowered shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price target on shares of Cabaletta Bio in a report on Monday, May 4th. Wells Fargo & Company raised their price objective on shares of Cabaletta Bio from $2.00 to $4.00 and gave the stock an “equal weight” rating in a report on Friday, May 15th. Jefferies Financial Group reissued a “buy” rating on shares of Cabaletta Bio in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

View Our Latest Stock Analysis on Cabaletta Bio

About Cabaletta Bio

(Get Free Report)

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.